InvestSMART

Nexalis Therapeutics Ltd (ASX: NX1) - Announcements

- Current share price for NX1 : $0.010

ASX company news and announcements for Nexalis Therapeutics Ltd (NX1) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nexalis Therapeutics Ltd (NX1) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nexalis Therapeutics Ltd (NX1), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nexalis Therapeutics Ltd (NX1)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Update on Funding Facility and Clinical Program 6 Jul 2026 11:48AM $0.010 $0.010 fallen by 0%
$3 Director Appointment/Resignation 25 Jun 2026 3:52PM $0.018 $0.010 fallen by 44.44%
$3 2026 AGM results 29 May 2026 6:23PM $0.023 $0.010 fallen by 56.52%
$3 2026 AGM slides 29 May 2026 4:14PM $0.023 $0.010 fallen by 56.52%
$3 Reinstatement to Official Quotation 28 May 2026 9:48AM $0.025 $0.010 fallen by 60%
$3 Binding Letter of Intent to replace existing $53m facility 28 May 2026 9:48AM $0.025 $0.010 fallen by 60%
$3 Suspension from Quotation 26 May 2026 10:34AM $0.025 $0.010 fallen by 60%
$3 Trading Halt 22 May 2026 9:38AM $0.025 $0.010 fallen by 60%
$3 Phase 1 IRX-616a Last Patient Last Dose 14 May 2026 11:33AM $0.022 $0.010 fallen by 54.55%
$3 Director Appointment/Resignation 13 May 2026 1:10PM $0.021 $0.010 fallen by 52.38%
$3 2026 AGM - Sample Proxy Form 30 Apr 2026 5:13PM $0.022 $0.010 fallen by 54.55%
$3 2026 AGM - Access Letter 30 Apr 2026 5:12PM $0.022 $0.010 fallen by 54.55%
$3 Notice of Annual General Meeting 30 Apr 2026 5:10PM $0.022 $0.010 fallen by 54.55%
$3 Mar26 Appendix 4C Cash Flow Report 30 Apr 2026 2:40PM $0.023 $0.010 fallen by 56.52%
$3 Mar26 Quarterly Activities Report 30 Apr 2026 2:40PM $0.023 $0.010 fallen by 56.52%
$3 Phase 1 IRX-616a Trial Advances to Final Cohort 28 Apr 2026 9:25AM $0.021 $0.010 fallen by 52.38%
$3 US Policy Market Advancement Supports SRX-25 TRD Treatment 23 Apr 2026 9:41AM $0.021 $0.010 fallen by 52.38%
$3 Significant Milestone - First Patient Screened IRX-211 Ph2 20 Apr 2026 9:59AM $0.023 $0.010 fallen by 56.52%
$3 Phase 1 IRX-616a Trial Advances - Positive Safety Review 17 Apr 2026 9:50AM $0.019 $0.010 fallen by 47.37%
$3 2025 Annual Report 31 Mar 2026 5:59PM $0.020 $0.010 fallen by 50%
$3 2025 Corporate Governance Statement and 4G 31 Mar 2026 5:41PM $0.020 $0.010 fallen by 50%
$3 Nexalis to present at the NWR Virtual Healthcare Conference 25 Mar 2026 2:34PM $0.020 $0.010 fallen by 50%
$3 First patient dosed in IRX-616a Phase 1 trial 19 Mar 2026 9:22AM $0.025 $0.010 fallen by 60%
$3 First eligible participant screened - phase 1 IRX-616a study 4 Mar 2026 11:26AM $0.021 $0.010 fallen by 52.38%
$3 Preliminary Final Report 27 Feb 2026 5:34PM $0.028 $0.010 fallen by 64.29%

1 - 25 of 37 results

Page 1 of 2

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.